{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06277999",
            "orgStudyIdInfo": {
                "id": "D8820C00001"
            },
            "organization": {
                "fullName": "AstraZeneca",
                "class": "INDUSTRY"
            },
            "briefTitle": "C.Difficile Observational Study",
            "officialTitle": "An Observational Study in Adults With Clostridioides Difficile Infection to Determine the Feasibility and Logistics of Biospecimen Collection, Transportation and Testing at Select US Study Sites",
            "therapeuticArea": [
                "Infectious Diseases"
            ],
            "study": "c-difficile-observational-study"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-22",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10-11",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-10-11",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-02-19",
            "studyFirstSubmitQcDate": "2024-02-19",
            "studyFirstPostDateStruct": {
                "date": "2024-02-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "AstraZeneca",
                "class": "INDUSTRY"
            }
        },
        "descriptionModule": {
            "briefSummary": "D8820C00001 is an exploratory, non-interventional, unblinded, observational study evaluating the acceptability, feasibility and performance of methods to collect, transport and test biospecimens in participants \u2265 18 years of age with an active CDI. Participants will also be monitored for recurring episodes of diarrhea and will need to complete validated PROs and study evaluation questionnaires",
            "detailedDescription": "The premise of D8820C00001 study is to monitor participants for recurring episodes of diarrhea and evaluate acceptability and feasibility of the use of the digital tools and patient outcome measures. The aim will be to enroll two cohorts of patients; the first will be the Monitoring cohort, enrolling a targeted minimum of 20 and a maximum of 100 participants who will be followed through Day 42, with a screening period from Day -5 to Day 1 (see Section 2.1.1). The second will be the Discard Stool cohort, enrolling up to 200 participants, who will not be followed during the study but who will provide consent for the use of any discarded stool specimens that will not be used for additional laboratory diagnostic testing ."
        },
        "conditionsModule": {
            "conditions": [
                "Clostridium Infections"
            ],
            "keywords": [
                "Clostridiodes difficile infection, C difficile"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "bioSpec": {
                "retention": "SAMPLES_WITH_DNA",
                "description": "stool, serum samples"
            },
            "enrollmentInfo": {
                "count": 100,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Monitoring Cohort",
                    "description": "Monitoring cohort will enroll a targeted minimum of 20 and a maximum of 100 participants \u2265 18 years of age who have been recently diagnosed with CDI by a licensed HCP and are receiving SOC antibiotic treatment, with treatment starting \u2264 5 days before study enrollment. Participants will be recruited from hospitals which perform C difficile laboratory diagnostic testing. Recruitment will occur over a 6-month period. Participants will be followed through Day 42, with a screening period from Day -5 to Day 1"
                },
                {
                    "label": "Discard Stool Cohort",
                    "description": "The Discard Stool cohort will include stool specimens from up to 200 participants, \u2265 18 years of age, who have been recently diagnosed with CDI by a licensed HCP within the past 7 days. Participants in this cohort will be screened at the study site to confirm eligibility. Following the screening period, there will be no additional study activities for the participant to complete."
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants that completed key study activities according to protocol",
                    "description": "Evaluation of the overall and individual completion rate of procedures and logistics involved in key study activities defined as:\n\n* Stool sample collection, transport, and processing.\n* Serum collection.\n* Identification of suspected rCDI using the participant monitoring strategy\n* Cdiff32, CDI-DaySyms and PGI-S PRO questionnaire completion rate during the SOC treatment period.",
                    "timeFrame": "from Day 1 to Day 42"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Time intervals across stool sample collection logistics",
                    "description": "All stools counted regardless of multiple stools per participant:\n\n* selected percentiles of empirical distribution of time taken for samples to be collected by courier for transport to central lab (split by geography, site, or home)\n* selected percentiles of empirical distribution of time taken of testing procedure or components thereof",
                    "timeFrame": "from Day 1 to Day 42"
                },
                {
                    "measure": "Participant Experience and site staff evaluation questionnaires",
                    "description": "Review of Participant Experience and site staff evaluation questionnaires for qualitative and quantitative feedback on factors which affect completion of study activities, including participant acceptability of study activities",
                    "timeFrame": "from Day 1 to Day 42"
                },
                {
                    "measure": "Gather information to assess logistics, resourcing and performance of different toxin detection assays (eg. EIA, PCR, CCNA)",
                    "description": "Number of samples completed in accordance to study protocol, time to complete testing, number of samples tested with stability window",
                    "timeFrame": "from Day 1 to Day 42"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female participants \u2265 18 years of age at the time of signing the informed consent\n2. Participants in the Monitoring and Discard Stool cohorts with an active treated CDI, defined as meeting all of the following:\n\n   * Either diarrhea, defined as \u2265 3 unformed stools in a 24 hour period, with the stool being measured as Types 5, 6, 7 on the Bristol Stool Scale or evidence of megacolon, or severe ileus.\n   * A positive local stool test results for toxigenic C difficile collected no more than 7 days before entry to the study or evidence of pseudomembranes demonstrated by endoscopy or histopathology.\n   * Receiving SOC therapy (including but not limited to metronidazole, vancomycin, fidaxomicin) for the treatment of CDI, initiated in the prior 5 days, at the time of enrollment.\n3. Able to complete all study assessments, and to understand and comply with study requirements/procedures (if applicable, with assistance by caregiver, surrogate, or legally authorized representative, or equivalent representative as locally defined) based on the assessment of the PI\n4. Able to complete the Follow-up period through Day 42 based on the assessment of the PI.\n5. If able, signed and dated written informed consent prior to any study specific procedures, including screening evaluations for participants who consent to participate in the Monitoring cohort. Ensure that participants who are considered by the Investigator clinically unable to consent at screening and who are entered into the study by the consent of a legally acceptable representative show evidence of assent, as applicable in accordance with local regulations.\n6. Signed and dated written information consent prior to collection and testing of stool samples for participants in the Discard Stool cohort\n\nExclusion Criteria:\n\n1. Employees of AstraZeneca, clinical study site, or any other individuals directly involved with the conduct of the study, or immediate family members of such individuals. Employees of the clinical site or immediate families of these individuals not directly involved in the clinical study will be permitted to participate.\n2. Deprived of freedom by an administrative or court order, or in emergency setting, or hospitalized involuntarily\n3. Absence of suitable venous access for serum sampling",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "130 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "\u2265 18 Years of Age (Adult, Older Adult )",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "AstraZeneca Clinical Study Information Center",
                    "role": "CONTACT",
                    "phone": "1-877-240-9479",
                    "email": "information.center@astrazeneca.com"
                }
            ],
            "locations": [
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Sacramento",
                    "state": "California",
                    "zip": "95817",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.58157,
                        "lon": -121.4944
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02115",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Saint Louis",
                    "state": "Missouri",
                    "zip": "63110",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.62727,
                        "lon": -90.19789
                    }
                },
                {
                    "facility": "Research Site",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Charleston",
                    "state": "South Carolina",
                    "zip": "29425",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.77657,
                        "lon": -79.93092
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000003015",
                    "term": "Clostridium Infections"
                }
            ],
            "ancestors": [
                {
                    "id": "D000016908",
                    "term": "Gram-Positive Bacterial Infections"
                },
                {
                    "id": "D000001424",
                    "term": "Bacterial Infections"
                },
                {
                    "id": "D000001423",
                    "term": "Bacterial Infections and Mycoses"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10283",
                    "name": "Infections",
                    "asFound": "Infection",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6247",
                    "name": "Clostridium Infections",
                    "asFound": "Clostridium Infections",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4722",
                    "name": "Bacterial Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M19252",
                    "name": "Gram-Positive Bacterial Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M12136",
                    "name": "Mycoses",
                    "relevance": "LOW"
                },
                {
                    "id": "M4721",
                    "name": "Bacterial Infections and Mycoses",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4222",
                    "name": "Anti-Bacterial Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4224",
                    "name": "Antibiotics, Antitubercular",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}